State Street Corp Boosts Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

State Street Corp increased its holdings in SI-BONE, Inc. (NASDAQ:SIBN) by 5.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,081,871 shares of the company’s stock after buying an additional 52,972 shares during the period. State Street Corp owned 2.58% of SI-BONE worth $15,125,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Millrace Asset Group Inc. purchased a new stake in SI-BONE during the 3rd quarter valued at $1,056,000. Champlain Investment Partners LLC grew its position in shares of SI-BONE by 14.7% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after buying an additional 358,821 shares during the period. Impax Asset Management Group plc boosted its position in shares of SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock worth $10,604,000 after purchasing an additional 221,604 shares in the last quarter. American Century Companies Inc. boosted its stake in SI-BONE by 22.8% in the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after purchasing an additional 368,637 shares in the last quarter. Finally, Divisadero Street Capital Management LP purchased a new position in SI-BONE in the 2nd quarter worth approximately $1,552,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SI-BONE Price Performance

Shares of NASDAQ SIBN opened at $13.27 on Wednesday. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $21.70. The stock’s 50-day moving average is $13.42 and its two-hundred day moving average is $14.08. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The company has a market cap of $556.52 million, a price-to-earnings ratio of -14.42 and a beta of 1.20.

Analyst Ratings Changes

Several research analysts have issued reports on SIBN shares. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a research report on Wednesday, November 20th. Truist Financial upped their price objective on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $23.00.

Insider Transactions at SI-BONE

In related news, CFO Anshul Maheshwari sold 2,439 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.68, for a total transaction of $30,926.52. Following the transaction, the chief financial officer now owns 194,623 shares of the company’s stock, valued at $2,467,819.64. This trade represents a 1.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Laura Francis sold 10,048 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.58, for a total value of $126,403.84. Following the sale, the chief executive officer now directly owns 482,875 shares of the company’s stock, valued at approximately $6,074,567.50. This represents a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,679 shares of company stock valued at $276,439. Insiders own 3.90% of the company’s stock.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.